Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Prof Angela Russell has been named as a ‘Rising Star’ in the BioBeat 50 Movers and Shakers in BioBusiness 2016 report.

Released annually, the report celebrates 50 outstanding women entrepreneurs and business leaders who are recognised for their contributions to global health innovation.  BioBeat’s founder Miranda Weston-Smith said that the report highlights those women who are “transforming today’s challenges into tomorrow’s opportunities” and are inspirational “pioneers who are setting the pace in laboratories, healthcare, entrepreneurial companies …“ among others. 

Angela Russell, Associate Professor of Medicinal Chemistry at the Departments of Chemistry and Pharmacology at the University of Oxford and co-founder of OxStem Ltd said “I am delighted to have been recognised in this report standing alongside some exceptional bioscience business leaders in the field.  Our research at OxStem has the potential to impact on the healthcare of millions worldwide with the approach of developing small molecule drugs in a wide range of therapeutic areas including cancer, neurodegenerative diseases and heart failure.  I hope that my nomination, together with the women featured in this report, helps to inspire the next generation of bioscience entrepreneurs”.

BioBeat 50 Movers and Shakers in BioBusiness 2016 report

Angela Russell, Associate Professor of Medicinal Chemistry, University of Oxford and Co-founder OxStem. Launched in May 2016, Angela co-founded OxStem, a revolutionary University of Oxford spin-out company focussed on regenerative medicine. OxStem aims to identify new classes of drugs that can reprogram or stimulate existing resident cells to repair tissues in age-related conditions including cancer, neurodegenerative diseases and heart failure. The company has raised £16.9 million this year, a record for a UK spin-out, to fund the development of a series of daughter companies.

In her academic career, with over 15 years medicinal chemistry experience, Angela has published over 80 original articles, book chapters and patent applications and co-founded the Oxford spin-out MuOx Ltd, acquired by Summit Therapeutics plc in 2013.

Similar stories

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Professor Trish Greenhalgh Highly Commended in the O²RB Excellence in Impact Awards 2021

Congratulations to Professor Trish Greenhalgh (Nuffield Department of Primary Care Health Sciences) who has been Highly Commended in the O²RB Excellence in Impact Awards 2021.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.